Analyst Price Targets — GMAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 27, 2026 10:09 am | Gregory Renza | Truist Financial | $40.00 | $26.89 | StreetInsider | Truist Securities Assumes Genmab A/S (GMAB) at Buy |
| April 30, 2026 10:12 am | — | H.C. Wainwright | $38.00 | $26.11 | TheFly | Genmab price target lowered to $38 from $40 at H.C. Wainwright |
| March 26, 2026 8:11 pm | — | Wolfe Research | $32.00 | $26.03 | TheFly | Genmab initiated with an Outperform at Wolfe Research |
| February 23, 2026 11:31 am | Michael Schmidt | Guggenheim | $40.00 | $29.29 | TheFly | Genmab price target lowered to $40 from $45 at Guggenheim |
| February 17, 2026 9:26 am | Benjamin Jackson | Jefferies | $41.50 | $30.03 | TheFly | Genmab resumed with a Buy at Jefferies |
| January 20, 2026 11:18 am | — | H.C. Wainwright | $39.00 | $32.25 | TheFly | Genmab price target lowered to $39 from $41 at H.C. Wainwright |
| November 6, 2025 8:03 pm | Asthika Goonewardene | Truist Financial | $48.00 | $28.84 | StreetInsider | Genmab A/S (GMAB) PT Lowered to $48 at Truist Securities |
| October 6, 2025 11:12 am | Asthika Goonewardene | Truist Financial | $49.00 | $33.56 | TheFly | Genmab price target raised to $49 from $46 at Truist |
| October 2, 2025 12:52 pm | — | H.C. Wainwright | $40.00 | $31.77 | TheFly | Genmab price target raised to $40 from $36 at H.C. Wainwright |
| September 29, 2025 5:04 pm | Jonathan Chang | Leerink Partners | $34.00 | $29.16 | TheFly | Genmab price target raised to $34 from $32 at Leerink |
Latest News for GMAB
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and…
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE FL-1 trial, fixed-duration TEPKINLYR2 demonstrated significantly superior progression-free survival and overall…
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 EPCORE® FL-1 trial that…
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for GMAB.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.